Predictors of the course of tardive dyskinesia in patients receiving neuroleptics

Biological Psychiatry

Volumn 32, Issue 7, 1992, Pages 580-594

  Bergen, Jenny ^a,b   Kitchin, Rowena ^a,b   Berry, Geoffrey ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE DECANOATE; LITHIUM; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX; TARDIVE DYSKINESIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUPHENAZINE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEUROLOGIC EXAMINATION; OBSERVER VARIATION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T;

EID: 0026454744     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(92)90071-7     Document Type: Article

References (38)

1. Akathisia variants and tardive dyskinesia
2. Tardive dyskinesia: a 3-year follow-up study
3. AIMS ratings—repeatability
4. The course of tardive dyskinesia in patients on long-term neuroleptics
5. Tardive dyskinesia: fluctuating patient or fluctuating rater
6. Long-term fluphenazine decanoate maintenance dosage requirement of chronic schizophrenic patients
7. A five-year follow-up study of tardive dyskinesia
8. A five-year prospective longitudinal study of tardive dyskinesia Factors predicting appearance of new cases
9. Factors related to tardive dyskinesia
10. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit
11. Tardive dyskinesia: A five year follow-up
12. Problems in the assessment of tardive dyskinesia
13. The natural history of tardive dyskinesia
14. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients
15. Tardive dyskinesia
16. Tardive dyskinesia A discontinuation study
17. Predictors of occurrence severity and course of tardive dyskinesia in an outpatient population
18. Heterogeneity of tardive dyskinesia: A multivariate analysis
19. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables
20. Tardive dyskinesia—reversible and persistent
21. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences
22. Integrating incidence and prevalence of tardive dyskinesia
23. Tardive dyskinesia Prevalence incidence and risk factors
24. Incidence of tardive dyskinesia: Five-year data from a prospective study
25. Tardive dyskinesia in schizophrenics under 60 years of age
26. Assessing agreement
27. Effect of different neuroleptics in tardive dyskinesia and parkinsonism A video-controlled multicenter study with chlorprothixene perphenazine haloperidol and haloperidol + biperiden
28. Tardive dyskinesia status: Stability or change
29. The Nithsdale Schizophrenia Survey. V. Follow-up or tardive dyskinesia at 31/2 years
30. Autoregressive modelling for the analysis of longitudinal data with unequally spaced examinations
31. Research diagnoses for tardive dyskinesia
32. Changes in prevalence, severity, and recovery in tardive dyskinesia with age
33. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia
34. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot fluphenthixol decanoate in chronic schizophrenic patients
35. Prevalence of tardive dyskinesia in an outpatient population
36. Mild tardive dyskinesia an 8-year follow-up study